• Amy M Valkovec, Shawn J Kram, James B Henderson, and Jerrold H Levy.
• Department of Pharmacy, Duke University Hospital, Durham, NC. Electronic address: amy.valkovec@duke.edu.
• J. Cardiothorac. Vasc. Anesth. 2023 Mar 1; 37 (3): 353359353-359.

ObjectiveThe altered pharmacokinetics of milrinone in renal impairment could result in an increased risk of cardiac arrhythmias. This study aimed to determine if there is an association between new-onset arrhythmias and renal impairment after cardiac surgery following milrinone administration.DesignA retrospective cohort study.SettingA single-center tertiary care hospital.ParticipantsAdult patients who received a milrinone infusion in the intensive care unit (ICU) setting after coronary artery bypass graft, valvuloplasty, annuloplasty, or a combination of these surgeries from July 1, 2014 to July 1, 2021. Renal impairment was defined using a creatinine clearance <60 mL/min, calculated using the Cockcroft-Gault equation.InterventionsPatients received a weight-based continuous intravenous infusion of milrinone.Measurements And Main ResultsThe primary outcome was the presence of new arrhythmias after the initial administration of a weight-based continuous intravenous infusion of milrinone postcardiac surgery. Of the 197 patients who met inclusion, there was no difference in the presence of new arrhythmias (42.9% v 40.3%, p = 0.76) or in the time to first new arrhythmia from milrinone initiation in those with renal impairment compared to those without renal impairment (29.1 hours v 33.3 hours, p = 0.54). Patients with renal impairment had a longer hospital stay than patients without renal impairment (17.5 days v 13.9 days, p = 0.016). Arrhythmia type, length of ICU stay, ICU mortality, and hospital mortality were not different between the cohorts.ConclusionsThere was no association between new arrhythmias, milrinone, and renal impairment in patients postcardiac surgery.Copyright © 2022 Elsevier Inc. All rights reserved.

14 keywords...

hide…